GlaxoSmithKline (NYSE:GSK) executive Ellen Strahlman is moving to Becton Dickinson (NYSE:BDX) to oversee medical affairs and R&D.

Strahlman will start in the newly created position of chief medical officer and senior vice president, research & development on April 22. Strahlman joined GSK in 2008 to become the company’s chief medical officer. More recently, she worked at GSK as senior medical advisor and global head of neglected tropical diseases.

As GSK’s chief medical officer, Dr. Strahlman was responsible for safety and patient matters for all programs in development and commercialized products in the vaccines, pharmaceutical and consumer businesses. Her responsibilities also included medical affairs, regulatory affairs, clinical safety and other areas.

Before joining GSK, Strahlman held executive posts at Merck, Novartis, Pfizer, and Bausch & Lomb that included oversight of the development and commercialization of proprietary and generic pharmaceuticals, drug delivery systems and medical devices.
Strahlman obtained her M.D. from the Johns Hopkins University School of Medicine, her M.H.Sc. from the Johns Hopkins School of Public Health and her B.A. degree from Harvard University.

Medical technology company BD develops and manufactures medical devices, instrument systems and reagents. The company operates a facilities across North Carolina, including a Research Triangle Park site. London-based GSK has its U.S. headquarters in RTP.